| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2008PNAS..105.8050K |
| P356 | DOI | 10.1073/PNAS.0801227105 |
| P932 | PMC publication ID | 2430357 |
| P698 | PubMed publication ID | 18541914 |
| P5875 | ResearchGate publication ID | 5315337 |
| P50 | author | Daniela Galimberti | Q32425219 |
| Elio Scarpini | Q32425238 | ||
| Carlos Cruchaga | Q37380520 | ||
| Alison Goate | Q45660395 | ||
| David M. Holtzman | Q56827171 | ||
| John C. Morris | Q56839763 | ||
| Anne M Fagan | Q66909797 | ||
| Chiara Fenoglio | Q71772625 | ||
| John S K Kauwe | Q91181931 | ||
| Petra Nowotny | Q114336794 | ||
| Sarah Bertelsen | Q114340344 | ||
| P2093 | author name string | Kevin Mayo | |
| P2860 | cites work | Statistical significance for genomewide studies | Q24681264 |
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Haploview: analysis and visualization of LD and haplotype maps | Q27860955 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| Processing of gene expression data generated by quantitative real-time RT-PCR. | Q30699578 | ||
| Biomarkers in the diagnosis of Alzheimer's disease: are we ready? | Q31050728 | ||
| CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden | Q33271198 | ||
| Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study | Q34287865 | ||
| Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration | Q35447435 | ||
| CSF biomarkers for mild cognitive impairment and early Alzheimer's disease | Q36095322 | ||
| Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. | Q36836607 | ||
| Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. | Q39173722 | ||
| The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts | Q40194429 | ||
| Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 | ||
| Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils | Q43718666 | ||
| The structure of the tau haplotype in controls and in progressive supranuclear palsy | Q47679261 | ||
| Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation | Q48237916 | ||
| Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease | Q48266934 | ||
| Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. | Q48499517 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. | Q53270733 | ||
| Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. | Q53285087 | ||
| A survey of genetic human cortical gene expression | Q57272923 | ||
| High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy | Q57306388 | ||
| Validation of clinical diagnostic criteria for Alzheimer's disease | Q68499881 | ||
| Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease | Q79442639 | ||
| Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease | Q79698091 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| P304 | page(s) | 8050-8054 | |
| P577 | publication date | 2008-06-09 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition | |
| P478 | volume | 105 |
| Q42131026 | A surrogate marker for Abeta42 production in the CNS. |
| Q38088622 | Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease |
| Q50920301 | Alzheimer disease: the quest for Alzheimer disease genes--focus on CSF tau. |
| Q38225911 | Alzheimer's disease genetics: from the bench to the clinic |
| Q34425904 | Alzheimer's disease risk genes and mechanisms of disease pathogenesis |
| Q37862502 | Alzheimer's disease: the challenge of the second century |
| Q31153643 | An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy |
| Q37066475 | An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome |
| Q37058143 | Antisense reduction of tau in adult mice protects against seizures |
| Q35484526 | Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease |
| Q57452847 | Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: A preliminary study in a Croatian cohort |
| Q30592862 | Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels |
| Q34959322 | Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels |
| Q37769104 | Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives |
| Q33556189 | Biomarkers in translational research of Alzheimer's disease |
| Q37953330 | CSF biomarkers for amyloid and tau pathology in Alzheimer's disease |
| Q37427768 | Calcium phosphatase calcineurin influences tau metabolism |
| Q36283394 | Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease |
| Q37227424 | Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects |
| Q33757828 | Cerebrospinal fluid biomarkers of Alzheimer's disease |
| Q37438267 | Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention |
| Q22253051 | Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people |
| Q48293542 | Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease |
| Q36466732 | Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies |
| Q36860474 | Finding risk in all the right places |
| Q33828778 | Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease |
| Q36186513 | Fluid biomarkers in Alzheimer disease |
| Q91635049 | GSK3β and Tau Protein in Alzheimer's Disease and Epilepsy |
| Q29417137 | GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease |
| Q40012093 | Genetic Architecture of MAPT Gene Region in Parkinson Disease Subtypes. |
| Q43132552 | Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease |
| Q37156046 | Genetic control of human brain transcript expression in Alzheimer disease |
| Q37692079 | Genetic discoveries in AD using CSF amyloid and tau. |
| Q34661700 | Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort |
| Q28079843 | Genetic variants associated with neurodegenerative Alzheimer disease in natural models |
| Q37416674 | Genome sequencing in a case of Niemann-Pick type C |
| Q43507480 | Genome-wide association study identifies MAPT locus influencing human plasma tau levels |
| Q38752201 | Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers |
| Q34394932 | Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation |
| Q61809067 | Identification of Alzheimer's Disease-Related Genes Based on Data Integration Method |
| Q43061614 | Interview with Alison Goate |
| Q37228718 | Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease |
| Q28474877 | Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts |
| Q58704067 | New endemic familial parkinsonism in south Moravia, Czech Republic and its genetical background |
| Q30572288 | Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement |
| Q46805247 | Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers |
| Q35844758 | Regulation of human MAPT gene expression |
| Q21144971 | SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease |
| Q33829008 | Targeting Abeta and tau in Alzheimer's disease, an early interim report |
| Q33980306 | Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease |
| Q40065021 | Tau as a biomarker of neurodegenerative diseases. |
| Q46788633 | Tau proteins in the temporal and frontal cortices in patients with vascular dementia. |
| Q31129910 | The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers |
| Q39246359 | The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis |
| Q34831241 | Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses |
| Q28082768 | Three dimensions of the amyloid hypothesis: time, space and 'wingmen' |
| Q33770749 | Transgenic Drosophila models of Alzheimer's disease and tauopathies |
| Q34544940 | Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels |
| Q37258203 | Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study |
Search more.